
The market is projected to grow from USD 172.00 million in 2025 to USD 351.21 million by 2035 because dried blood spots are cheap to collect and ship, and newborn screening programs use a card for nearly every baby. Newborn screening, home sampling, decentralized trials and new screening programmes support steady growth, lifting the market to USD 245.78 million by 2030 and sustaining a CAGR of 7.40% from 2026 to 2035. DBS sampling supports genomics, precision medicine and telehealth-based home testing.

Analyst View: We built the estimate from newborn births screened, DBS use in trials, home testing and infectious disease programmes and average card prices by region, cross-checked against supplier activity. Published estimates for this exact scope are limited, so our value is evidence-based.
| Driver | Impact | ≈ CAGR Contribution | Time Horizon | Key Regions |
| Universal newborn screening | High | +2.89 pp | Short to long term | Global, strongest in North America |
| Home sampling grows | Medium | +2.44 pp | Medium to long term | Global, fastest uptake in Asia Pacific |
| Decentralised trials | Medium | +2.08 pp | Short to medium term | Global |
| Remote infectious disease testing | Low | +1.63 pp | Long term | Developed and emerging markets |
Note: Contributions are indicative estimates of each factor's effect on annual growth.
Sources: Expert interviews, secondary sources, Towards Healthcare database and Towards Healthcare analysts.
Taken together, these drivers add about 9.03 percentage points to the annual growth of the dried blood spot collection cards market, with universal newborn screening having the largest effect. Their influence is strongest in North America, while uptake grows fastest in Asia Pacific.
| Restraint | Impact | ≈ Negative CAGR Contribution | Time Horizon | Key Regions |
| Haematocrit effects on accuracy | High | -0.73 pp | Short to medium term | Global |
| Analyte stability limits | High | -0.54 pp | Medium term | Price-sensitive and emerging markets |
| Lab validation burden | Medium | -0.36 pp | Short term | North America and other mature markets |
Note: Contributions are indicative estimates of each factor's effect on annual growth.
Sources: Expert interviews, secondary sources, Towards Healthcare database and Towards Healthcare analysts.
These restraints are expected to reduce annual growth of the dried blood spot collection cards market by about 1.63 percentage points, led by haematocrit effects on accuracy. Their effect eases over the forecast period as suppliers, buyers and regulators adapt, leaving a net CAGR of 7.40% from 2026 to 2035.
Volumetric DBS devices are being increasingly adopted, which creates opportunities for accurate and standardized blood sample collection. The expansion of newborn screening programs in Asia is fueling the demand for DBS cards in early disease detection. Rising use of type 1 diabetes and genomic screening drives market demand in specialized testing applications. Growing interest in preventive healthcare is creating opportunities for the use of DBS cards in at-home health testing kits. The demand for biobanking is increasing, which fuels the adoption of DBS cards to facilitate long-term sample collection, preservation, and storage.

Note: 2025 is the base year; 2035 shares and CAGRs are forecasts.
Sources: Expert interviews, secondary sources, Towards Healthcare database, and Towards Healthcare analysts.
Standard Cellulose Cards accounted for 58.00% of the market in 2025 and are projected to expand at a CAGR of 6.55% during the forecast period. Standard cellulose cards lead because newborn screening programmes use them for every baby. This segment is expected to grow slower than the overall market between 2026 and 2035.
Treated & Nucleic Acid Cards stabilise DNA and RNA for genetic and infectious disease tests. This segment is expected to grow at a slower rate than the overall market over the forecast period.
Volumetric DBS Devices grow fastest because they collect a fixed blood volume for accurate drug and biomarker tests. The volumetric DBS devices segment is expected to grow faster than the overall market from 2026 to 2035.
Segment Outlook: Standard Cellulose Cards remains the largest product segment through 2035, holding about 53.59% of the market in 2035, while Volumetric DBS Devices records the highest CAGR of 9.95% from 2026 to 2035. Although Volumetric DBS Devices starts from the smallest base, its faster growth shows how demand is shifting within the dried blood spot collection cards market.

Note: 2025 is the base year; 2035 shares and CAGRs are forecasts.
Sources: Expert interviews, secondary sources, Towards Healthcare database and Towards Healthcare analysts.
Newborn Screening held a 52.00% share in 2025 and is projected to expand at a CAGR of 6.90% from 2026 to 2035. Newborn screening leads because nearly all births in many countries are screened with DBS cards. This segment is expected to grow slower than the overall market over the forecast period.
Infectious Disease Testing uses DBS for HIV and hepatitis in remote areas. The infectious disease testing segment is expected to grow broadly in line with the overall market between 2026 and 2035.
Therapeutic Drug Monitoring & PK grow the fastest in trials. This segment is expected to grow faster than the market from 2026 to 2035.
Genetic & Biomarker Testing uses DBS for home sampling. The genetic & biomarker testing segment is expected to grow broadly in line with the overall market over the forecast period.
Others uses include research. This segment is expected to grow broadly in line with the market from 2026 to 2035.
Segment Outlook: Newborn Screening remains the largest application segment through 2035, holding about 49.63% of the market in 2035, while Therapeutic Drug Monitoring & PK records the highest CAGR of 9.30% from 2026 to 2035. Others holds the smallest share today and serves more specialised needs within the dried blood spot collection cards market.

Note: 2025 is the base year; 2035 shares and CAGRs are forecasts.
Sources: Expert interviews, secondary sources, Towards Healthcare database, and Towards Healthcare analysts.
Public Health & Newborn Screening Labs accounted for 50.00% of the dried blood spot collection cards market in 2025 and is projected to expand at a CAGR of 6.85% from 2026 to 2035. Public health and newborn screening labs lead because they buy cards in national volumes. This segment is expected to grow slower than the overall market over the forecast period.
Hospitals & Clinics segment is expected to grow broadly in line with the overall market between 2026 and 2035.
Pharma Companies & CROs are growing the fastest with decentralised trials. The pharma companies & CROs segment is expected to grow faster than the overall market over the forecast period.
Research & Consumer Labs use home kits, the research & consumer labs segment is expected to grow broadly in line with the overall market from 2026 to 2035.
Segment Outlook: Public Health & Newborn Screening Labs remains the largest end user segment through 2035, holding about 47.50% of the market in 2035, while Pharma Companies & CROs record the highest CAGR of 9.25% from 2026 to 2035. Research & Consumer Labs holds the smallest share today and serves more specialised needs within the dried blood spot collection cards market.
Analyst View: Segment shares were allocated from demand, product portfolios and pricing in each category. Standard Cellulose Cards, Newborn Screening and Public Health & Newborn Screening Labs lead their categories because they meet the core needs of today's buyers. We expect Volumetric DBS Devices, Therapeutic Drug Monitoring & PK and Pharma Companies & CROs to gain share as newer technologies, users and applications grow faster.

Note: 2025 is the base year; 2035 shares and CAGRs are forecasts.
Sources: Expert interviews, secondary sources, Towards Healthcare database and Towards Healthcare analysts.
North America accounted for 36.00% of the market in 2025 and is projected to expand at a CAGR of 6.83% from 2026 to 2035. North America leads because of universal newborn screening, decentralized trials and home testing companies. North America is expected to grow slower than the overall market over the forecast period.
Europe has national newborn screening and new type 1 diabetes and genomic screening pilots. Europe is expected to grow broadly in line with the overall market throughout the forecast period.
Asia Pacific grows fastest as newborn screening expands in China, India and Southeast Asia. Asia Pacific is expected to grow faster than the market over the forecast period.
Latin America has an expanding newborn screening ecosystem. This region is expected to grow broadly in line with the overall market between 2026 and 2035.
Middle East & Africa use DBS for HIV and newborn programs. This region is expected to grow broadly in line with the overall market over the forecast period.
Analyst View: Regional shares were built from demand, installed base, spending and supplier presence in each region. North America leads because of its mature demand base and strong suppliers. We assign Asia Pacific the highest growth premium because investment, adoption and capacity are expanding fastest there.

| Rank | Company Name | 2025 Share (%) | Key Products / Business | Headquarters |
| 1 | Revvity | 12.79% | Newborn screening cards and GSP systems | United States |
| 2 | Cytiva (Danaher) | 11.63% | Whatman 903 protein saver and FTA cards | United States |
| 3 | Ahlstrom | 6.98% | Filter paper DBS cards | Finland |
| 4 | Neoteryx (Trajan) | 4.65% | Mitra VAMS volumetric devices | Australia |
| 5 | Capitainer | 2.33% | qDBS volumetric cards | Sweden |
| 6 | Tasso | 2.33% | Tasso-M20 dried volumetric blood collection | United States |
| 7 | Thermo Fisher Scientific | 1.74% | DBS collection products | United States |
| 8 | ID Biological Systems | 1.74% | Specimen collection cards | United States |
| 9 | Spot On Sciences | 1.16% | HemaSpot blood collection devices | United States |
| 10 | Hemaxis | 1.16% | Hemaxis DB10 volumetric device | Switzerland |
Note: Company shares are 2025 estimates.
Sources: Company press releases, expert interviews, secondary sources, Towards Healthcare database and Towards Healthcare analysts.
Revvity led the market with 12.79% of revenue in 2025, followed by Cytiva (Danaher) at 11.63% share and Ahlstrom at 6.98% share. Revvity is the leader owing to newborn screening cards and GSP systems, Cytiva (Danaher) competes with Whatman 903 protein saver and FTA cards, and Ahlstrom offers filter paper DBS cards. Neoteryx (Trajan), Capitainer, Tasso, Thermo Fisher Scientific, ID Biological Systems, Spot On Sciences and Hemaxis compete through Mitra VAMS volumetric devices, qDBS volumetric cards, Tasso-M20 dried volumetric blood collection, DBS collection products, specimen collection cards, hemaSpot blood collection devices and hemaxis DB10 volumetric device. The top 10 companies accounted for a 46.51% share in 2025, while the remaining 53.49% was shared among many regional card printers and kit assemblers. The market is concentrated among a few filter paper suppliers, and competition revolves around paper consistency, regulatory clearance, volumetric accuracy, stability, program contracts and price.
Revvity: Revvity is headquartered in the United States. It held 12.79% of revenue in 2025. Its offering revolves around Newborn screening cards and GSP systems. In the Towards Healthcare Companies Quadrant it is positioned as a Leader.
Cytiva (Danaher): Cytiva (Danaher) has its global headquarters in the United States. It held an 11.63% share in 2025. Its offering centres on Whatman 903 protein saver and FTA cards. Cytiva (Danaher) is positioned as a Leader in the Towards Healthcare Companies Quadrant.
Ahlstrom: Ahlstrom has its corporate headquarters in Finland. The company held an 6.98% share of the dried blood spot collection cards market in 2025. Its offering centres on Filter paper DBS cards. In the Towards Healthcare Companies Quadrant it is positioned as a Leader.
Neoteryx (Trajan): Neoteryx (Trajan) is headquartered in Australia. It held 4.65% of the market in 2025. Its offering revolves around Mitra VAMS volumetric devices. The company has been positioned as a Leader in the Towards Healthcare Companies Quadrant.
Capitainer: Capitainer is headquartered in Sweden. Capitainer held a 2.33% share of the dried blood spot collection cards market in 2025. Its offering centres on qDBS volumetric cards. In the Towards Healthcare Companies Quadrant it is positioned as a Leader.
Tasso: Tasso has its corporate headquarters in the United States. It held 2.33% of revenue in 2025. Its portfolio consists of Tasso-M20 dried volumetric blood collection. In the Towards Healthcare Companies Quadrant it is positioned as a Leader.
Thermo Fisher Scientific: Thermo Fisher Scientific is headquartered in the United States. It held a 1.74% share in 2025. Its offering centres on DBS collection products. Thermo Fisher Scientific is positioned as a Innovator in the Towards Healthcare Companies Quadrant.
ID Biological Systems: ID Biological Systems has its global headquarters in the United States. It held 1.74% of the market in 2025. Its offering revolves around Specimen collection cards. In the Towards Healthcare Companies Quadrant it is positioned as an Innovator.
Spot On Sciences: Spot On Sciences has its corporate headquarters in the United States. It held 1.16% of revenue in 2025. The company’s portfolio comprises HemaSpot blood collection devices. The company has been positioned as an Innovator in the Towards Healthcare Companies Quadrant.
Hemaxis: Hemaxis, part of DBS System SA, is headquartered in Switzerland. It held a 1.16% share in 2025. Its offering centres on Hemaxis DB10 volumetric device. In the Towards Healthcare Companies Quadrant it is positioned as an Innovator.
The dried blood spot collection cards ecosystem links paper & material suppliers, card & device makers, kit assemblers, users and regulators, with each stage adding value before products reach end users.
| Ecosystem Stage | Role in the Market | Key Companies |
| Paper & Material Suppliers | Make filter paper | Cytiva, Ahlstrom |
| Card & Device Makers | Make cards and volumetric devices | Revvity, Trajan, Capitainer |
| Kit Assemblers | Build home and trial kits | Kit and logistics firms |
| Users | Collect and test samples | Newborn labs, hospitals, CROs, consumer labs |
| Regulators | Clear devices and set screening rules | FDA, CLSI NBS01, EU IVDR |
Sources: Company press releases, expert interviews, secondary sources, Towards Healthcare database and Towards Healthcare analysts.
Paper & Material Suppliers: Make filter paper. Key participants include Cytiva, Ahlstrom.
Card & Device Makers: Make cards and volumetric devices. Key participants include Revvity, Trajan, Capitainer.
Kit Assemblers: Build home and trial kits. Key participants include Kit and logistics firms.
Users: Collect and test samples. Key participants include Newborn labs, hospitals, CROs, and consumer labs.
Regulators: Clear devices and set screening rules. Key participants include FDA, CLSI NBS01, EU IVDR.
Value in the dried blood spot collection cards market flows from upstream material and technology suppliers to manufacturers and service providers, then through distribution partners to end users. Companies that integrate several stages or build long-term relationships with end users capture a larger share of this value.
The Towards Healthcare Companies Quadrant positions key participants in the dried blood spot collection cards market by market strength, reflecting revenue scale, market share and geographic reach, and by innovation and growth strategy, reflecting product portfolio breadth, research and development intensity, and partnerships. Positions reflect each company's estimated 2025 share of the dried blood spot collection cards market and our assessment of its product innovation, portfolio breadth, and partnerships.
Sources: Company press releases, expert interviews, secondary sources, Towards Healthcare database and Towards Healthcare analysts.
Leaders: Revvity, Cytiva (Danaher), Ahlstrom, Neoteryx (Trajan), Capitainer and Tasso combine high market share with broad portfolios and strong innovation.
Innovators: Thermo Fisher Scientific, ID Biological Systems, Spot On Sciences and Hemaxis bring newer technologies and specialised products.
By Product
By Application
By End User
By Region
The market is defined as cards and devices that collect capillary blood as dried spots, including cellulose filter paper cards, treated cards that stabilize DNA and RNA, and volumetric DBS devices, used for newborn screening, infectious disease testing, therapeutic drug monitoring and pharmacokinetics, genetic and biomarker testing, and remote home sampling by public health and newborn screening laboratories, hospitals and clinics, pharmaceutical companies and CROs, and research and consumer testing laboratories. The 2025 base year was built bottom-up from demand volumes and average prices by product, application and end user and region, and checked top-down against the market-specific revenues of leading companies and published estimates. Segment, regional and company values were allocated from product, application and end user and region demand. Key estimates were verified by cross-checking company disclosures, regulatory and industry data and published third-party estimates, and inputs that could not be reconciled were excluded. All segment, regional and company figures were reconciled to the same 2025 base year, and the 2026-2035 forecast, which applies a constant CAGR from the 2025 base, was recalculated and validated.
Analyst View: The market is set for steady expansion as newborn screening and related demand keep growing. Our estimate links value to underlying demand, installed base and pricing, so the forecast follows real adoption rather than headline hype. The main upside comes from volumetric devices and new screening programmes, while the main risks are haematocrit effects and analyte stability limits.